Part 4/9:
With 20% of the global population and 30% of all cancer patients, the urgency for improved healthcare solutions in China is undeniable. Currently, only a mere four of the 42 globally approved cancer drugs in the past five years are available to Chinese patients, underscoring the vast potential for growth within this sector.
While foreign investments, especially from U.S. biotech companies, are increasing, the Chinese government aims to provide universal access to basic healthcare by 2020. This assurance further fuels optimism surrounding the Chinese healthcare system, especially considering the expanding affluent middle class and an aging demographic.